US Stock MarketDetailed Quotes

NMRA Neumora Therapeutics

Watchlist

1.740
+0.050+2.96%

Close Feb 14 16:00 ET

1.730
-0.010-0.57%

Post 20:01 ET

281.12MMarket Cap1.57P/E (TTM)

Neumora Therapeutics Stock Forum

Teddy123

Feb 13 06:21

Neumora Therapeutics Announces Leadership Transition

$Neumora Therapeutics (NMRA.US)$
Leadership Powershift at Neumora: Co-Founder Takes Helm as 3 Major Clinical Trials Near Completion

Odin570

Feb 5 15:09

$Neumora Therapeutics (NMRA.US)$ Levi & Korsinsky notifies investors that it has commenced an investigation of Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc.") (NASDAQ:NMRA) concerning possible violations of federal securities laws

缘来 :

Report
Reply

Cancel Reply
siong long : where you get this news source? is real?

Report
Reply

Cancel Reply
minority153 : info comes the "market insider" website
Stock News
Neumora Therapeutics, Inc. (NMRA) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
Neumora Therapeutics, Inc. (NMRA) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
PRESS RELEASE ACCESS Newswire
Feb. 6, 2025, 07:30 AM
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc.") (NASDAQ:NMRA) concerning possible violations of federal securities laws.
On January 2, 2025, Neumora announced its experimental depression treatment failed in the first of three studies planned by the biotech company. As part of this announcement, Neumora disclosed that navacaprant showed no difference from a placebo in treating depression symptoms in the Phase III Koastal-1 trial. Analysts expressed surprise and concern at the Company's "worst-case scenario" for the program.
Following this news, NMRA's stock price plummeted 81% to close at $1.97 per share on January 2, 2025. To obtain additional information, go to:
https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=127478&wire=1
or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/
SOURCE: Levi & Korsinsky, LLP

Report
Reply

Cancel Reply

Professor XL

Feb 5 02:51

$Neumora Therapeutics (NMRA.US)$ april 17 $22.50 watch mark my words $22.50

玛丽旺旺财

Jan 15 09:46

$Neumora Therapeutics (NMRA.US)$
Market on fire and this garbage crashing??

Trytosaveabit

Jan 7 14:41

Grrr!

$Neumora Therapeutics (NMRA.US)$ That quick jump to 2.86 and drop stopped me out at 2.65! Grrr! Oh well 50% ill take any day! Its just not glorious like those 100%+! Hehehe